Moody Lynn & Lieberson LLC Has $35.29 Million Stake in Abbott Laboratories $ABT

Moody Lynn & Lieberson LLC lessened its position in Abbott Laboratories (NYSE:ABT) by 1.5% in the third quarter, Holdings Channel.com reports. The firm owned 263,455 shares of the healthcare product maker’s stock after selling 4,090 shares during the quarter. Abbott Laboratories comprises 1.9% of Moody Lynn & Lieberson LLC’s portfolio, making the stock its 17th biggest holding. Moody Lynn & Lieberson LLC’s holdings in Abbott Laboratories were worth $35,287,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Consilium Wealth Advisory LLC increased its position in Abbott Laboratories by 1.4% in the 3rd quarter. Consilium Wealth Advisory LLC now owns 7,557 shares of the healthcare product maker’s stock valued at $1,012,000 after acquiring an additional 102 shares during the period. Calamos Wealth Management LLC increased its holdings in Abbott Laboratories by 90.1% in the third quarter. Calamos Wealth Management LLC now owns 16,114 shares of the healthcare product maker’s stock valued at $2,158,000 after purchasing an additional 7,638 shares during the period. Aljian Capital Management LLC increased its holdings in Abbott Laboratories by 39.1% in the third quarter. Aljian Capital Management LLC now owns 4,897 shares of the healthcare product maker’s stock valued at $656,000 after purchasing an additional 1,377 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in Abbott Laboratories by 42.2% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 826,268 shares of the healthcare product maker’s stock worth $110,670,000 after purchasing an additional 245,400 shares during the last quarter. Finally, Sax Wealth Advisors LLC grew its position in shares of Abbott Laboratories by 6.9% in the 3rd quarter. Sax Wealth Advisors LLC now owns 7,344 shares of the healthcare product maker’s stock valued at $984,000 after buying an additional 472 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 1.0%

Shares of NYSE ABT opened at $125.83 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market cap of $218.80 billion, a PE ratio of 15.77, a P/E/G ratio of 2.27 and a beta of 0.72. The company’s fifty day simple moving average is $126.11 and its 200 day simple moving average is $129.75. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. The firm had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.0%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s payout ratio is 29.57%.

Analyst Ratings Changes

ABT has been the topic of several analyst reports. Sanford C. Bernstein upped their target price on Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Jefferies Financial Group upped their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Wells Fargo & Company lifted their target price on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $147.00 price target on shares of Abbott Laboratories in a research report on Thursday, October 16th. Finally, Raymond James Financial lifted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.